Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

By sjmartinez • January 16, 2025

Jaiswal V, Hanif M, Mashkoor Y, Jaiswal A, Prasad T, Rajak K, Khan MS, Mentz RJ, Fonarow GC. Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC Adv. 2024 Nov 15;3(12):101405. doi: 10.1016/j.jacadv.2024.101405. PMID: 39817087; PMCID: PMC11734025.

Tags: amyloidosis, Cardiology/Epi, Outcomes, Publications, SGLT2 inhibitors, transthyretin amyloid cardiomyopathy

Sudden cardiac arrest: Limitations in risk-stratification and treatment, and the potential for digital technologies and artificial intelligence to improve prediction and outcomes

Srivats S, Zghyer F, Shahrori Z, Albert C, Al-Khatib SM, Chugh S, Etheridge SP, Goldberger ZD, Gopinathannair R, Lakkireddy D, Morin DP, Perez MV, Rottmann[...]

Distal electrical stimulation enhances neuromuscular reinnervation and satellite cell differentiation for functional recovery

Lin CW, Chen SH, Cheng SM, Chung TC, Liu W, Hwang DY, Li S, Lin SC, Hsueh YY. Distal electrical stimulation enhances neuromuscular reinnervation and[...]

Implementing a Cardiology Quality Incentive Program to Improve Guideline-Directed Medical Therapy

Cho DJ, Bokhoor PI, Dermenchyan A, Brownell N, Delavin NL, Furlong S, Hoo J, Tibbe T, Chen LY, Vangala S, Waterman BA, Han M, Fonarow[...]